Literature DB >> 1572478

Direct effect of gonadotropin-releasing hormone agonists on the rabbit ovarian follicle.

Y Yoshimura1, Y Nakamura, M Ando, S Shiokawa, N Koyama, T Nanno.   

Abstract

OBJECTIVE: To determine if gonadotropin-releasing hormone agonist (GnRH-a)-induced oocyte maturation and degeneration can be attributed to the direct actions on the follicle.
DESIGN: Mature rabbit follicle culture.
INTERVENTIONS: The mature follicles were cultured with human chorionic gonadotropin (hCG) (100 ng/mL), buserelin acetate (10(-9) to 10(-6) M), leuprolide acetate (10(-9) to 10(-6) M), or buserelin acetate (10(-7) M) with a GnRH antagonist (10(-8) to 10(-6) M) for 14 hours. MAIN OUTCOME MEASURES: The percentage of oocytes achieving germinal vesicle breakdown, the oocyte degeneration rate, prostaglandins (PG) production by mature follicles, and the frequency of fertilization and embryonic development.
RESULTS: Gonadotropin-releasing hormone agonist induced the meiotic maturation of follicle-enclosed oocytes in a dose-dependent manner while concomitantly increasing oocyte degeneration. The simultaneous addition of GnRH antagonist inhibited significantly GnRH-a-induced oocyte maturation and PG production by the mature follicles. Furthermore, a GnRH antagonist reversed the oocyte degeneration rate that had been increased by GnRH-a. The rates of normal fertilization and early embryonic development were significantly reduced in the oocytes matured by GnRH-a as compared with those matured by hCG.
CONCLUSIONS: Gonadotropin-releasing hormone agonist acts directly on mature rabbit follicles to trigger the oocytes to undergo meiotic maturation, but oocytes matured in vitro by GnRH-a are not necessarily cytoplasmically mature.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1572478     DOI: 10.1016/s0015-0282(16)55029-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

1.  Treatment variables in relation to oocyte maturation: lessons from a clinical micromanipulation-assisted in vitro fertilization program.

Authors:  O M Avrech; G A Goldman; O Rufas; A Stein; S Amit; I Yoles; H Pinkas; B Fisch
Journal:  J Assist Reprod Genet       Date:  1997-07       Impact factor: 3.412

2.  Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization.

Authors:  Eun Mi Chang; Ji Eun Han; Hyung Jae Won; You Shin Kim; Tae Ki Yoon; Woo Sik Lee
Journal:  J Assist Reprod Genet       Date:  2011-12-08       Impact factor: 3.412

3.  Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase--a function of improved embryo quality.

Authors:  M Schachter; S Friedler; A Raziel; D Strassburger; O Bern; R Ron-el
Journal:  J Assist Reprod Genet       Date:  2001-04       Impact factor: 3.412

4.  Ovarian hyper-response to administration of an GnRH-agonist without gonadotropins.

Authors:  Hyun Tae Park; Hyo Sook Bae; Tak Kim; Sun Haeng Kim
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

5.  In vitro fertility rate of 129 strain is improved by buserelin (gonadotropin-releasing hormone) administration prior to superovulation.

Authors:  K Vasudevan; J M Sztein
Journal:  Lab Anim       Date:  2012-10       Impact factor: 2.471

Review 6.  Management of poor responders in IVF: is there anything new?

Authors:  Filippo Ubaldi; Alberto Vaiarelli; Rosario D'Anna; Laura Rienzi
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.